NCT03464942View on ClinicalTrials.gov

Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

June 22, 2023

Study Completion Date

June 22, 2023

Conditions
Breast Cancer
Interventions
RADIATION

SABR

Single Dose Group: this group will receive 20 Gy of radiation in a single dose within 10 days of randomisation Fractionated Dose: Participants in this dose will receive a total of 24Gy of radiation given as 3 separate fractions of 8 Gy each.

DRUG

Atezolizumab

All participants will commence atezolizumab (within 5 days of last SABR dose) 1200 mg every 3 weeks for 24 months

Trial Locations (1)

3000

Peter MacCallum Cancer Centre, Melbourne

All Listed Sponsors
collaborator

Trans Tasman Radiation Oncology Group

OTHER

lead

Peter MacCallum Cancer Centre, Australia

OTHER

NCT03464942 - Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter